Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Bladder Cancer

  Free Subscription

Articles published in J Urol

Retrieve available abstracts of 202 articles:
HTML format

Single Articles

    June 2020
    Re: National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.
    J Urol. 2020 Jun 30:101097JU0000000000001175. doi: 10.1097/JU.0000000000001175.

    Re: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jun 30:101097JU000000000000117501.

  3. ATALA A
    Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer Progression.
    J Urol. 2020 Jun 18:101097JU000000000000117901.

    Re: The Impact of Non-Urothelial Variant Histology on Oncological Outcomes following Radical Cystectomy.
    J Urol. 2020;203:1060.

    May 2020
    Re: Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries with Bladder Cancer: A SEER-Medicare Analysis.
    J Urol. 2020 May 13:101097JU000000000000110204.

    Re: Assessment of Quality of Life, Information, and Supportive Care Needs in Patients with Muscle and Non-Muscle Invasive Bladder Cancer across the Illness Trajectory.
    J Urol. 2020 May 12:101097JU000000000000111402.
    PubMed     Abstract available

  7. ATALA A
    Re: A Genetically Defined Disease Model Reveals that Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 May 12:101097JU0000000000001117. doi: 10.1097/JU.0000000000001117.

    Re: Association between Treatment of Superficial Bladder Cancer and 10-Year Mortality in Older Adults with Multiple Chronic Conditions.
    J Urol. 2020 May 12:101097JU000000000000111401.

    Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases.
    J Urol. 2020;203:880.

    Editorial Comment.
    J Urol. 2020;203:908-909.

    April 2020
  11. ROUPRET M, Gontero P, McCracken SRC, Dudderidge T, et al
    Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Non Muscle Invasive Bladder Cancer Follow up: A Blinded, Prospective Cohort, Multicentric European Study.
    J Urol. 2020 Apr 21:101097JU0000000000001084. doi: 10.1097/JU.0000000000001084.
    PubMed     Abstract available

  12. ATALA A
    Re: Hypermethylation of FOXA1 and Allelic Loss of PTEN Drive Squamous Differentiation and Promote Heterogeneity in Bladder Cancer.
    J Urol. 2020 Apr 9:101097JU0000000000001058. doi: 10.1097/JU.0000000000001058.

  13. CHANG SS
    Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    J Urol. 2020 Apr 9:101097JU0000000000001055. doi: 10.1097/JU.0000000000001055.

  14. BECERRA MF, Venkatramani V, Reis IM, Soodana-Prakash N, et al
    Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial - A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.
    J Urol. 2020 Apr 9:101097JU0000000000001029. doi: 10.1097/JU.0000000000001029.
    PubMed     Abstract available

  15. CHANG SS
    Re: Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery after Surgery Protocol.
    J Urol. 2020;203:660.

    March 2020
  16. SHARMA V, Wymer KM, Borah BJ, Saigal CS, et al
    Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer.
    J Urol. 2020 Mar 19:101097JU0000000000001023. doi: 10.1097/JU.0000000000001023.
    PubMed     Abstract available

  17. CHANG SS
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2020 Mar 17:101097JU000000000000099902.

    Editorial Comment.
    J Urol. 2020;203:511.

  19. MONTORSI F, Moschini M, Gallina A, Briganti A, et al
    Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2020;203:624.

  20. MULLER G, Butea-Bocu M, Brock O, Hanske J, et al
    Association between Development of Metabolic Acidosis and Improvement of Urinary Continence after Ileal Neobladder Creation.
    J Urol. 2020;203:585-590.
    PubMed     Abstract available

  21. ZHANG JH, Ericson KJ, Thomas LJ, Knorr J, et al
    Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach.
    J Urol. 2020;203:512-521.
    PubMed     Abstract available

  22. VENKATRAMANI V, Reis IM, Castle EP, Gonzalgo ML, et al
    Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.
    J Urol. 2020;203:522-529.
    PubMed     Abstract available

    February 2020
  23. ATALA A
    Re: 5-Methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAs.
    J Urol. 2020 Feb 12:101097JU0000000000000781. doi: 10.1097/JU.0000000000000781.

  24. ATALA A
    Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression.
    J Urol. 2020 Feb 12:101097JU000000000000078101.

  25. WEINER AB, Kundu SD
    Editorial Comment.
    J Urol. 2020;203:290-291.

  26. CHANG SS
    Re: Effectiveness of Adjuvant Chemotherapy after Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-Invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    J Urol. 2020;203:250.

    January 2020
  27. ATALA A
    Re: Epigenetic Loss of AOX1 Expression via EZH2 Leads to Metabolic Deregulations and Promotes Bladder Cancer Progression.
    J Urol. 2020 Jan 13:101097JU000000000000073202.

  28. CHANG SS
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU0000000000000729. doi: 10.1097/JU.0000000000000729.

  29. CHANG SS
    Re: Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU000000000000072902.

  30. SIEGEL C
    Re: Delayed (18)F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer.
    J Urol. 2020 Jan 7:101097JU0000000000000718. doi: 10.1097/JU.0000000000000718.

    Re: Frailty as a Predictor of Complications after Radical Cystectomy: A Prospective Study of Various Preoperative Assessments.
    J Urol. 2020;203:9.

  32. ALDHAAM NA, Elsayed AS, Jing Z, Richstone L, et al
    Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC.
    J Urol. 2020;203:57-61.
    PubMed     Abstract available

  33. CHECK DK, Leo MC, Banegas MP, Bulkley JE, et al
    Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy.
    J Urol. 2020;203:159-163.
    PubMed     Abstract available

    December 2019
  34. STEINBERG RL, Thomas LJ, Brooks N, Mott SL, et al
    Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer.
    J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688.
    PubMed     Abstract available

  35. CHANG SS
    Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance Bacillus Calmette-G
    J Urol. 2019 Dec 3:101097JU0000000000000676. doi: 10.1097/JU.0000000000000676.

  36. WEIN AJ
    Re: Long-Term Follow-Up after Cystectomy for Bladder Pain Syndrome: Pain Status, Sexual Function and Quality of Life.
    J Urol. 2019;202:1101-1102.

  37. LENIS AT
    Editorial Comment.
    J Urol. 2019;202:1134-1135.

  38. ALBERSHEIM J, Sathianathen NJ, Zabell J, Renier J, et al
    Skeletal Muscle and Fat Mass Indexes Predict Discharge Disposition after Radical Cystectomy.
    J Urol. 2019;202:1143-1149.
    PubMed     Abstract available

  39. SIGHINOLFI MC, Rocco B, Micali S, Bianchi G, et al
    Re: Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;202:1271-1272.

  40. RASKOLNIKOV D, Brown B, Holt SK, Ball AL, et al
    Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis.
    J Urol. 2019;202:1136-1142.
    PubMed     Abstract available

  41. AL HUSSEIN AL AWAMLH B, Shoag JE, Ravikumar V, Posada L, et al
    Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
    J Urol. 2019;202:1248-1254.
    PubMed     Abstract available

    November 2019
    Re: Reduced Recurrence of Low-Grade Papillary Bladder Tumors Associated with Asymptomatic Bacteriuria.
    J Urol. 2019;202:849.

  43. ATALA A
    Re: Recurrent Activating Mutations of PPARgamma Associated with Luminal Bladder Tumors.
    J Urol. 2019;202:869.

  44. PEYTON CC, Reich RR, Tang D, Alford B, et al
    Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review.
    J Urol. 2019;202:913-919.
    PubMed     Abstract available

  45. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
    Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2019;202:927-935.
    PubMed     Abstract available

  46. MCALPINE K, Lavallee LT, Stacey D, Moodley P, et al
    Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy.
    J Urol. 2019;202:1001-1007.
    PubMed     Abstract available

    October 2019
  47. LOTAN Y
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 25:101097JU0000000000000625. doi: 10.1097/JU.0000000000000625.

  48. MONTORSI F, Moschini M, Briganti A
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 24:101097JU0000000000000624. doi: 10.1097/JU.0000000000000624.

  49. CHANG SS
    Re: Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease beyond Overall Incidence.
    J Urol. 2019 Oct 16:101097JU0000000000000599. doi: 10.1097/JU.0000000000000599.

  50. RITCH CR, Velasquez MC, Kwon D, Becerra MF, et al
    Utility and Validation of the AUA/SUO Risk Grouping for Non-muscle Invasive Bladder Cancer in a Contemporary Cohort.
    J Urol. 2019 Oct 14:101097JU0000000000000593. doi: 10.1097/JU.0000000000000593.
    PubMed     Abstract available

  51. LABBATE C, Werntz RP, Adamic B, Steinberg GD, et al
    The Impact of Omission of Intraoperative Frozen Section Prior to Orthotopic Neobladder Reconstruction.
    J Urol. 2019;202:763-769.
    PubMed     Abstract available

  52. SINGLA N
    Editorial Comment.
    J Urol. 2019;202:688.

  53. SEFIK E, Bozkurt IH, Basmaci I, Celik S, et al
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819.

  54. LUO Y, Wang X, Xiao Y
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819-820.

    September 2019
  55. LIEM EI, Oddens JR, Vernooij R, Li R, et al
    The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guerin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Da
    J Urol. 2019 Sep 24:101097JU0000000000000566. doi: 10.1097/JU.0000000000000566.
    PubMed     Abstract available

    Re: The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients with Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-Matched Study.
    J Urol. 2019 Sep 18:101097JU0000000000000559. doi: 10.1097/JU.0000000000000559.

    Re: Disparities in Bladder Cancer Treatment and Survival amongst Elderly Patients with a Pre-Existing Mental Illness.
    J Urol. 2019 Sep 18:10109701JU00005857524193298.

  58. CHANG SS
    Re: Prognostic Significance of Lymphatic, Vascular and Perineural Invasion for Bladder Cancer Patients Treated by Radical Cystectomy.
    J Urol. 2019 Sep 18:10109701JU0000585772800505.

    Re: High-Precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-Day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.
    J Urol. 2019 Sep 18:10109701JU00005857643430962.

    Re: Cost-Effectiveness of Surveillance Schedules in Older Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU00005857564955687.

    Re: Evaluation of Cause of Death after Radical Cystectomy for Patients with Bladder Cancer: The Impact of Age at the Time of Surgery.
    J Urol. 2019 Sep 18:10109701JU000058576026685.

  62. CHANG SS
    Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU000058576872427.

  63. MOREY AF
    Re: Dual Prosthetic Implantation after Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors.
    J Urol. 2019 Sep 13:101097JU0000000000000549. doi: 10.1097/JU.0000000000000549.

  64. ATALA A
    Re: Bladder Cancer Extracellular Vesicles Drive Tumorigenesis by Inducing the Unfolded Protein Response in Endoplasmic Reticulum of Nonmalignant Cells.
    J Urol. 2019 Sep 12:10109701JU00005851520364998.

    Re: Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2019;202:456-457.

  66. KHANNA A, Saarela O, Lawson K, Finelli A, et al
    Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes.
    J Urol. 2019;202:490-497.
    PubMed     Abstract available

    August 2019
  67. BJURLIN MA, Nielsen ME
    Editorial Comment.
    J Urol. 2019;202:246.

  68. RICHARD PO, Bashir S, Riverin BD, Alibhai SMH, et al
    Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study.
    J Urol. 2019;202:319-325.
    PubMed     Abstract available

    July 2019
  69. CHANG SS
    Re: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
    J Urol. 2019 Jul 31:10109701JU00005794560657170.

  70. CHANG SS
    Re: Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model.
    J Urol. 2019 Jul 31:101097JU0000000000000479. doi: 10.1097/JU.0000000000000479.

  71. CHANG SS
    Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    J Urol. 2019 Jul 31:10109701JU00005794608369953.

  72. ATALA A
    Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research.
    J Urol. 2019 Jul 9:10109701JU000057698421354.

  73. CHANG SS
    Re: Population-Based Assessment of Racial/Ethnic Differences in Utilization of Radical Cystectomy for Patients Diagnosed with Bladder Cancer.
    J Urol. 2019 Jul 9:10109701JU0000576988055492.

  74. FILIPPOU P, Smith AB
    Editorial Comment.
    J Urol. 2019;202:89.

    June 2019
  75. KUROIWA K, Inokuchi J, Nishiyama H, Kojima T, et al
    Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    J Urol. 2019 Jun 28:101097JU0000000000000422. doi: 10.1097/JU.0000000000000422.
    PubMed     Abstract available

  76. RAVVAZ K, Weissert JA, Downs TM
    American Urological Association Non-muscle Invasive Bladder Cancer Risk Model Validation: Should patient age be added to the risk model?
    J Urol. 2019 Jun 12:101097JU0000000000000389. doi: 10.1097/JU.0000000000000389.
    PubMed     Abstract available

  77. CHANG SS
    Re: Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-A Prospective Double-Blind Clinical Study.
    J Urol. 2019 Jun 10:10109701JU00005691889046242.

  78. CHANG SS
    Re: Disseminated Mycobacterium bovis Infection Post-Kidney Transplant following Remote Intravesical BCG Therapy for Bladder Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000381. doi: 10.1097/JU.0000000000000381.

  79. WEI L, Hussein AA, Ma Y, Azabdaftari G, et al
    Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;201:1105-1114.
    PubMed     Abstract available

    May 2019
  80. WESTERGREN DO, Gardmark T, Lindhagen L, Chau A, et al
    A Nationwide Population Based Analysis of Organ-Confined Muscle-Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014.
    J Urol. 2019 May 30:101097JU0000000000000350. doi: 10.1097/JU.0000000000000350.
    PubMed     Abstract available

  81. LOTAN Y, Inman BA, Davis LG, Kassouf W, et al
    Evaluation of the UroVysion Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 May 23:101097JU0000000000000355. doi: 10.1097/JU.0000000000000355.
    PubMed     Abstract available

  82. MORERA DS, Lahorewala SS, Belew D, Ghosh S, et al
    Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA.
    J Urol. 2019 May 21:101097JU0000000000000351. doi: 10.1097/JU.0000000000000351.
    PubMed     Abstract available

  83. CHANG SS
    Re: Discrepancies in Staging, Treatment, and Delays to Treatment May Explain Disparities in Bladder Cancer Outcomes: An Update from the National Cancer Data Base (2004-2013).
    J Urol. 2019 May 8:10109701JU000055962335906.

  84. CHANG SS
    Re: Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients.
    J Urol. 2019 May 8:10109701JU00005596222828385.

  85. CHANG SS
    Re: Extended versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    J Urol. 2019 May 8:101097JU0000000000000332. doi: 10.1097/JU.0000000000000332.

  86. MENG MV, Gschwend JE, Shore N, Grossfeld GD, et al
    Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer.
    J Urol. 2019 May 1:101097JU0000000000000297. doi: 10.1097/JU.0000000000000297.
    PubMed     Abstract available

  87. WOLDU SL
    Editorial Comment.
    J Urol. 2019;201:901.

  88. METCALF M, Glazyrine V, Glavin K, Dahlgren A, et al
    The Feasibility of a Health Care Application in the Treatment of Patients Undergoing Radical Cystectomy.
    J Urol. 2019;201:902-908.
    PubMed     Abstract available

  89. ROTH B, Furrer MA, Giannakis I, Vartolomei MD, et al
    Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution.
    J Urol. 2019;201:909-915.
    PubMed     Abstract available

    April 2019
  90. ABUFARAJ M, Tabung FK, Shariat SF, Moschini M, et al
    Association between inflammatory potential of diet and bladder cancer risk:Results from three US prospective cohort studies.
    J Urol. 2019 Apr 22:101097JU0000000000000279. doi: 10.1097/JU.0000000000000279.
    PubMed     Abstract available

    March 2019
  91. CHANG SS
    Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy.
    J Urol. 2019 Mar 29:10109701JU0000557728168538.

  92. CHANG SS
    Re: Contemporary Treatment Patterns and Outcomes of Sarcomatoid Bladder Cancer.
    J Urol. 2019 Mar 29:101097JU0000000000000252. doi: 10.1097/JU.0000000000000252.

  93. CHANG SS
    Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Mar 29:10109701JU000055772739723.

  94. CHANG SS
    Re: Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients with Recurrent Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU000055464194059.

  95. CHANG SS
    Re: Partial Bladder Boost Using Lipiodol Marking during Image-Guided Radiotherapy for Bladder Cancer.
    J Urol. 2019 Mar 13:101097JU0000000000000218. doi: 10.1097/JU.0000000000000218.

    Re: Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives Concerning the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    J Urol. 2019 Mar 13:10109701JU00005546361960937.

    Re: Outcomes of Radiosensitisation in Elderly Patients with Advanced Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU00005546347386712.

    Re: Real-World Effectiveness of Chemotherapy in Elderly Patients with Metastatic Bladder Cancer in the United States.
    J Urol. 2019 Mar 13:10109701JU0000554635814908.

  99. WINTERS BR, Wen L, Holt SK, Dash A, et al
    Does the diagnosis of bladder cancer lead to higher rates of smoking cessation? Findings from the Medicare Health Outcomes Survey.
    J Urol. 2019 Mar 5:101097JU0000000000000206. doi: 10.1097/JU.0000000000000206.
    PubMed     Abstract available

  100. LEO MC, Gilbert SM, Wendel CS, Krouse RS, et al
    Development of a goal elicitation measure to support bladder cancer patients' choice about urinary diversion.
    J Urol. 2019 Mar 5:101097JU0000000000000203. doi: 10.1097/JU.0000000000000203.
    PubMed     Abstract available

  101. CHANG SS
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
    J Urol. 2019;201:442.

  102. CHANG SS
    Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer.
    J Urol. 2019;201:441-442.

  103. CHANG SS
    Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer.
    J Urol. 2019;201:441.

  104. PARKER DC, Abboud MA, Patel SG
    Is Routine Removal of the Ovaries Advisable during Radical Cystectomy?
    J Urol. 2019;201:455-456.

    February 2019
  105. CHANG SS
    Re: Predicting Local Failure after Radical Cystectomy in Patients with Bladder Cancer: .
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000166.

  106. CHANG SS
    Re: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554054.35801.

  107. CHANG SS
    Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554055.35801.

    Re: Impact of Psychiatric Illness on Decreased Survival in Elderly Patients with Bladder Cancer in the United States.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000162.

    Re: Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553996.66966.

    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553995.59343.

  111. ATALA A
    Re: Identification of MicroR-106b as a Prognostic Biomarker of p53-Like Bladder Cancers by ActMiR.
    J Urol. 2019;201:231.

  112. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: .
    J Urol. 2019;201:225-226.

  113. WANG DS
    Re: A Prospective Randomized Pilot Study Evaluating an ERAS Protocol versus a Standard Protocol for Patients Treated with Radical Cystectomy and Urinary Diversion for Bladder Cancer.
    J Urol. 2019 Feb 1. doi: 10.1097/JU.0000000000000154.

    January 2019
  114. EBRAHIMI H, Amini E, Pishgar F, Moghaddam SS, et al
    Global, Regional, and National Burden of Bladder Cancer, 1990 - 2016: Results from the Global Burden of Disease Study 2016.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000025.
    PubMed     Abstract available

  115. CHANG SS
    Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Therapy.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000097.

  116. CHANG SS
    Re: Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553308.83315.

  117. ATALA A
    Re: LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553307.75692.

  118. CHANG SS
    Re: Pathologic Response in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Is Therapeutic Effect Owing to Chemotherapy or TURBT?
    J Urol. 2019;201:30.

  119. CHANG SS
    Re: Adjuvant Sandwich Chemotherapy plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: A Randomized Phase 2 Trial.
    J Urol. 2019;201:29.

  120. KIMURA S, Mari A, Foerster B, Abufaraj M, et al
    Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:46-53.
    PubMed     Abstract available

    December 2018
  121. XUE W, Yang L, Wei Q
    Re: Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: R. S. Liao, M. Gupta, Z. R. Schwen, H. D. Patel, M. Kates, M. H. Johnson, N. M. Hahn, D. McConkey, T. J.
    J Urol. 2018;200:1378-1379.

    November 2018
  122. ATALA A
    Re: An FGFR3/MYC Positive Feedback Loop Provides New Opportunities for Targeted Therapies in Bladder Cancers.
    J Urol. 2018;200:947-948.

  123. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion.
    J Urol. 2018;200:942-943.

    Re: Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    J Urol. 2018;200:922.

    October 2018
  125. PEYTON CC, Henriksen C, Reich RR, Azizi M, et al
    Estimating Minimally Important Differences for the Bladder Cancer Index Using Distribution- and Anchor-Based Approaches.
    J Urol. 2018 Oct 17. pii: S0022-5347(18)43986-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available

  126. FRANSEN VAN DE PUTTE EE, Pos F, Doodeman B, van Rhijn BWG, et al
    Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43985-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available

  127. CHANG SS
    Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:696-697.

    September 2018
  128. CHANG SS
    Re: Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:497.

  129. CHANG SS
    Re: Association between Number of Endoscopic Resections and Utilization of bacillus Calmette-Guerin Therapy for Patients with High-Grade, Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:496-497.

    Editorial Comment.
    J Urol. 2018;200:539-540.

    August 2018
    Editorial Comment.
    J Urol. 2018;200:290.

  132. PATEL S, Cookson MS
    Editorial Comment.
    J Urol. 2018;200:290-291.

    Re: Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268.
    J Urol. 2018;200:457-458.

  134. HAMILTON-REEVES JM, Stanley A, Bechtel MD, Yankee TM, et al
    Perioperative Immunonutrition Modulates Inflammatory Response after Radical Cystectomy: Results of a Pilot Randomized Controlled Clinical Trial.
    J Urol. 2018;200:292-301.
    PubMed     Abstract available

    July 2018
  135. HAIFLER M
    Editorial Comment.
    J Urol. 2018;200:59-60.

  136. FILSON CP
    Editorial Comment.
    J Urol. 2018;200:59.

  137. MEEKS JJ, Glaser AP
    Editorial Comment.
    J Urol. 2018;200:60.

    June 2018
  138. DOWNS TM, Weissert JA, Ravvaz K
    Can we improve non-muscle-invasive bladder cancer (NMIBC) guideline adherence with smarter risk-stratification?
    J Urol. 2018 Jun 12. pii: S0022-5347(18)43357-5. doi: 10.1016/j.juro.2018.

  139. AUDENET F, Waingankar N, Ferket BS, Niglio SA, et al
    Effectiveness of transurethral resection (TUR) plus systemic chemotherapy as definitive treatment for muscle-invasive bladder cancer (MIBC) in population-level data.
    J Urol. 2018 Jun 4. pii: S0022-5347(18)43313-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available

    May 2018
  140. MAZZA P, Moran GW, Li G, Robins DJ, et al
    Conservative Management Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.
    J Urol. 2018 May 19. pii: S0022-5347(18)43234-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available

  141. MAKELA VJ, Kotsar A, Tammela TL, Murtola TJ, et al
    Bladder cancer survival in men using 5-alpha-reductase inhibitors.
    J Urol. 2018 May 3. pii: S0022-5347(18)43085-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available

  142. ATALA A
    Re: Evasion of Immunosurveillance by Genomic Alterations of PPARgamma/RXRalpha in Bladder Cancer.
    J Urol. 2018;199:1115-1116.

  143. CHANG SS
    Re: Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    J Urol. 2018;199:1111-1112.

  144. CHANG SS
    Re: Intravesical rAd-IFNalpha/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    J Urol. 2018;199:1110-1111.

    April 2018
  145. CHANG SS
    Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Urol. 2018;199:891-892.

  146. CHANG SS
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    J Urol. 2018;199:891-892.

    March 2018
  147. KAPADIA AA, Acevedo AM, Liu JJ, Garzotto M, et al
    Unconventional Bladder Preservation: Factors predicting Failure to Receive Definitive Surgery following Chemotherapy for Non-metastatic Muscle Invasive Bladder Cancer within the National Cancer Database.
    J Urol. 2018 Mar 15. pii: S0022-5347(18)42581-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available

  148. PERLIS N, Krahn MD, Boehme KE, Alibhai SM, et al
    The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
    J Urol. 2018 Mar 9. pii: S0022-5347(18)42498-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available

    February 2018
  149. UHLIG A, Amir Hosseini AS, Simon J, Lotz J, et al
    Gender-specific differences in disease-free, cancer-specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39380-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  150. CHANG SS
    Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer.
    J Urol. 2018;199:341-342.

  151. CHANG SS
    Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guerin.
    J Urol. 2018;199:340-342.

    January 2018
  152. ZARGAR H, Shah JB, van Rhijn BW, Daneshmand S, et al
    Neoadjuvant dose dense MVAC versus GC in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy.
    J Urol. 2018 Jan 9. pii: S0022-5347(18)30036-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  153. NIWA N, Kikuchi E, Matsumoto K, Kosaka T, et al
    Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with non-muscle-invasive bladder cancer.
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30006-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  154. CHANG SS
    Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guerin: Results from European Organ
    J Urol. 2018;199:26.

  155. CHANG SS
    Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.
    J Urol. 2018;199:25-26.

    December 2017
  156. CHANG SS
    Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Urol. 2017;198:1208.

  157. DANESHMAND S, Patel S, Lotan Y, Pohar K, et al
    Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (Hal) in the Surveillance of Bladder Cancer: A Phase Iii, Comparative, Multi-Center Study.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

    November 2017
  158. CASILLA-LENNON MM, Choi SK, Deal AM, Bensen JT, et al
    Financial Toxicity in Bladder Cancer Patients- Reasons for Delay in Care and Effect on Quality of Life.
    J Urol. 2017 Nov 16. pii: S0022-5347(17)77917-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  159. KOUMPAN Y, Jaeger M, Mizubuti GB, Tanzola R, et al
    Spinal Anesthesia is Associated with Lower Recurrence Rates after Resection of Non-Muscle Invasive Bladder Cancer.
    J Urol. 2017 Nov 14. pii: S0022-5347(17)77909-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  160. ATALA A
    Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:985.

  161. ATALA A
    Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    J Urol. 2017;198:984-985.

  162. ATALA A
    Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer.
    J Urol. 2017;198:983-985.

  163. CHANG SS
    Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2017;198:979-980.

  164. CHANG SS
    Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:978-980.

    October 2017
  165. WALLACE E, Higuchi R, Satya M, McCann L, et al
    Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  166. RYAN S, Serrell EC, Karabon P, Mills G, et al
    The Association Between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77715-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

    September 2017
  167. CHANG SS
    Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation.
    J Urol. 2017;198:482-483.

  168. CHANG SS
    Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    J Urol. 2017;198:482-483.

  169. SANCHEZ A, Wszolek MF, Niemierko A, Clayman RH, et al
    Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77426-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

    August 2017
  170. NARAYAN VM, Adejoro O, Schwartz I, Ziegelmann M, et al
    The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77411-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  171. SMITH ZL, Johnson SC, Golan S, McGinnis JR, et al
    Fistulous complications following radical cystectomy for bladder cancer: analysis of a large modern cohort.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77409-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  172. HURLE R, Lazzeri M, Vanni E, Lughezzani G, et al
    Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project.
    J Urol. 2017 Aug 25. pii: S0022-5347(17)77391-0. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  173. ATALA A
    Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo.
    J Urol. 2017;198:258-259.

  174. CHANG SS
    Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    J Urol. 2017;198:255.

    July 2017
  175. CHANG SS
    Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    J Urol. 2017;198:40.

  176. CHANG SS
    Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    J Urol. 2017;198:39-41.

    June 2017
  177. ARK JT, Alvarez JR, Koyama T, Bassett JC, et al
    Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race, and risk factors for bladder cancer.
    J Urol. 2017 Jun 24. pii: S0022-5347(17)76746-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  178. LAGUNA MP
    Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel.
    J Urol. 2017;197:1437-1438.

    April 2017
  179. CHANG SS, Bochner BH, Chou R, Dreicer R, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
    J Urol. 2017 Apr 26. pii: S0022-5347(17)57836-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  180. RAVVAZ K, Walz ME, Weissert JA, Downs TM, et al
    Predicting non-muscle invasive bladder cancer recurrence and progression in a US population.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54785-0. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

    March 2017
  181. KIM JH, Chung BI
    Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5alpha-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and
    J Urol. 2017 Mar 29. pii: S0022-5347(17)30226-4. doi: 10.1016/j.juro.2017.

  182. BOEHM BE, Cornell JE, Wang H, Mukherjee N, et al
    Efficacy of Bacillus Calmette-guerin Strains for the Treatment of non-muscle Invasive Bladder Cancer: a Systematic Review and Network Meta-analysis.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39246-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  183. TOBERT CM, Hamilton-Reeves JM, Norian LA, Hung C, et al
    The Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications on Cystectomy for Bladder Cancer.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39247-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available

  184. CHANG SS
    Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer.
    J Urol. 2017;197.

    February 2017
    Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis: R. Chou, S. Selph, D. I. Buckley, R. Fu, J. C. Griffin, S. Gr
    J Urol. 2017 Feb 6. pii: S0022-5347(16)32070-5. doi: 10.1016/j.juro.2016.

    January 2017
  186. CHANG SS
    Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;197:52-54.

  187. CHANG SS
    Re: PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    J Urol. 2017;197:53-54.

    December 2016
  188. BEUKERS W, van der Keur KA, Kandimalla R, Vergouwe Y, et al
    FGFR3, TERT and OTX1 as urinary biomarker combination for surveillance of bladder cancer patients in a large prospective multicenter study.
    J Urol. 2016 Dec 31. pii: S0022-5347(16)32099-7. doi: 10.1016/j.juro.2016.
    PubMed     Abstract available

  189. SHENOY SP, Marla PK, Sharma P, Batchu CK, et al
    Re: Sequential bacillus Calmette-Guerin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes: C. Gan, S. Amery, K. Chatterton, M. S. Khan, K. Thomas and T
    J Urol. 2016 Dec 28. pii: S0022-5347(16)31927-9. doi: 10.1016/j.juro.2016.

  190. CHOU R, Selph S, Buckley DI, Fu R, et al
    Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2016 Dec 24. pii: S0022-5347(16)32091-2. doi: 10.1016/j.juro.2016.
    PubMed     Abstract available

    October 2016
  191. CHOU R, Selph S, Buckley DI, Fu R, et al
    Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis.
    J Urol. 2016 Oct 22. pii: S0022-5347(16)31585-3. doi: 10.1016/j.juro.2016.
    PubMed     Abstract available

  192. ATALA A
    Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness.
    J Urol. 2016;196:1314.

  193. CHANG SS
    Re: Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor after Transurethral Resection for Bladder Cancer.
    J Urol. 2016;196:1045.

  194. CHANG SS
    Re: Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: One-Year Results of a Multicentre Prospective Cohort Study.
    J Urol. 2016;196:1045-6.

  195. CHANG SS
    Re: Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer: A Prospective, Blinded, International and Multicenter Validation Study.
    J Urol. 2016;196:1044-6.

    May 2016
  196. WANG DS
    Re: Long-Term Changes in Renal Function Outcomes following Radical Cystectomy and Urinary Diversion.
    J Urol. 2016;195:1511.

  197. MOREY AF
    Re: Outcomes of the Endoscopic Treatment of Bladder Neck Contractures in the Orthotopic Neobladder.
    J Urol. 2016;195:1508-9.

  198. CHANG SS
    Re: Oncologic Outcomes following Robot-Assisted Radical Cystectomy with Minimum 5-Year Follow-up: The Roswell Park Cancer Institute Experience.
    J Urol. 2016;195:1381-2.

  199. VENKATRAMANI V, Parekh DJ
    Editorial Comment.
    J Urol. 2016;195:1375.

  200. KRISHNAN N, Liu X, Lavieri MS, Hu M, et al
    A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy.
    J Urol. 2016;195:1362-7.
    PubMed     Abstract available

  201. HUSSEIN AA, Hashmi Z, Dibaj S, Altartir T, et al
    Reoperations following Robot-Assisted Radical Cystectomy: A Decade of Experience.
    J Urol. 2016;195:1368-76.
    PubMed     Abstract available

    April 2016
  202. PATEL S, Cookson MS
    Radical Cystectomy-The Waiting is the Hardest Part...or is it?
    J Urol. 2016;195.

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.